Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 2/20 | 0.64 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.62 |
| ▸ | METTL14 | Q9HCE5 | 1/20 | 0.62 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10131093 | 1.00 | ADK (0.64) | ADKMETTL3METTL14SLC29A1 | |
| SCHEMBL10160817 | 1.00 | ADK (0.64) | ADKMETTL3METTL14SLC29A1 | |
| SCHEMBL13005628 | 1.00 | ADK (0.64) | ADKMETTL3METTL14SLC29A1 | |
| SCHEMBL14440901 | 0.99 | ADK (0.63) | ADKMETTL3METTL14SLC29A1 | |
| SCHEMBL14440630 | 0.99 | ADK (0.63) | ADKMETTL3METTL14SLC29A1 | |
| SCHEMBL14429029 | 0.90 | SLC29A1 (0.54) | ADKSLC29A1 | |
| SCHEMBL14429079 | 0.90 | SLC29A1 (0.54) | ADKSLC29A1 | |
| SCHEMBL23544706 | 0.89 | ADK (0.53) | ADKMETTL3METTL14 | |
| SCHEMBL1689454 | 0.89 | METTL3 (0.55) | ADKMETTL3SLC29A1 | |
| SCHEMBL18636459 | 0.89 | ADK (0.53) | ADKMETTL3METTL14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4705313-A2 | 4'-SUBSTITUTED NUCLEOSIDES AND NUCLEOTIDES AS ANTIVIRAL AGENTS | The Scripps Research Institute (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20250041324-A1 | CYCLIC DINUCLEOTIDES AS AGONISTS OF STIMULATOR OF INTERFERON GENE DEPENDENT SIGNALLING | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2025-02-06 | — | — | US | disclosed |
| WO-2024227159-A2 | 4'-SUBSTITUTED NUCLEOSIDES AND NUCLEOTIDES AS ANTIVIRAL AGENTS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-10-31 | — | — | WO | disclosed |
| US-12036231-B2 | Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-07-16 | — | — | US | disclosed |
| US-12036231-B2 | Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-07-16 | — | — | US | disclosed |
| US-12036231-B2 | Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-07-16 | — | — | US | disclosed |
| EP-3585904-B1 | USE OF BIOMARKERS IN IDENTIFYING CANCER PATIENTS THAT WILL BE RESPONSIVE TO TREATMENT WITH A PRMT5 INHIBITOR | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-29 | — | — | EP | disclosed |
| US-20230330127-A1 | 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-19 | — | — | US | disclosed |
| WO-2023152709-A1 | RNA POLYMERASE INHIBITORS AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-08-17 | — | — | WO | disclosed |
| EP-4219496-A1 | NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN Pharmaceutica NV (BE) | 2023-08-02 | — | — | EP | disclosed |
| US-7713941-B2 | Tricyclic nucleosides or nucleotides as therapeutic agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2010-05-11 | — | — | US | disclosed |
| US-20080200423-A1 | Novel Tricyclic Nucleosides or Nucleotides as Therapeutic Agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2008-08-21 | — | — | US | disclosed |
| US-20080200423-A1 | Novel Tricyclic Nucleosides or Nucleotides as Therapeutic Agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2008-08-21 | — | — | US | disclosed |
| EP-1848718-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-10-31 | — | — | EP | disclosed |
| US-7268119-B2 | Tricyclic nucleosides or nucleotides as therapeutic agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-09-11 | — | — | US | disclosed |
| US-7268119-B2 | Tricyclic nucleosides or nucleotides as therapeutic agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-09-11 | — | — | US | disclosed |
| US-20070135363-A1 | NOVEL TRICYCLIC NUCLEOSIDES OR NUCLEOTIDES AS THERAPEUTIC AGENTS | BIOTA, INC. (US) | 2007-06-14 | — | — | US | disclosed |
| US-20070135363-A1 | NOVEL TRICYCLIC NUCLEOSIDES OR NUCLEOTIDES AS THERAPEUTIC AGENTS | BIOTA, INC. (US) | 2007-06-14 | — | — | US | disclosed |
| US-20060189636-A1 | Inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-08-24 | — | — | US | disclosed |
| WO-2006084281-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135363-A1 | NOVEL TRICYCLIC NUCLEOSIDES OR NUCLEOTIDES AS THERAPEUTIC AGENTS | NTPCR, NME1, NME2 | ADK 119/4885METTL3 1748/4885METTL14 3038/4885 |
| US-20080200423-A1 | Novel Tricyclic Nucleosides or Nucleotides as Therapeutic Agents | NME1, NME2, NTPCR | ADK 203/4885METTL3 1389/4885METTL14 3209/4885 |
| US-12036231-B2 | Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling | STING1, IRF3, CGAS | ADK 370/4885METTL3 4785/4885METTL14 4707/4885 |
| US-20250041324-A1 | CYCLIC DINUCLEOTIDES AS AGONISTS OF STIMULATOR OF INTERFERON GENE DEPENDENT SIGNALLING | STING1, IRF3, CGAS | ADK 370/4885METTL3 4785/4885METTL14 4707/4885 |
| US-20230330127-A1 | 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | PRMT5, PRMT6, PRMT1 | ADK 299/4885METTL3 69/4885METTL14 301/4885 |
| US-20060189636-A1 | Inhibitors of E1 activating enzymes | ECE1, RNASE1, RCE1 | ADK 1068/4885METTL3 4649/4885METTL14 4573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.